Cedars-sinai Medical Center

Sungyong You

Michael R Freeman

Ramachandran Murali

Mirja Rotinen

Beatrice Knudsen

Jayoung Kim

Provided herein are compositions and methods for treating, inhibiting and/or reducing the severity of cancer in subjects in need thereof. The methods include providing an agent that inhibits expression or activity of ONECUT2 and administering a therapeutically effective amount of the agent so as to treat, inhibit and/or reduce the severity of cancer in the subject.

Compositions and methods for treating cancer

Provided herein are compositions and methods for treating, inhibiting and/or reducing the severity of neuroblastoma, small cell lung cancer (SCLC), large cell neuroendocrine cancer (LCNEC), large-cell carcinoma (LCC), squamous cell carcinoma (SqCC), and/or adenocarcinoma (AC) in subjects in need thereof. The methods include providing an agent that inhibits expression or activity of ONECUT2 and administering a therapeutically effective amount of the agent so as to treat, inhibit and/or reduce the severity of neuroblastoma, small cell lung cancer (SCLC), large cell neuroendocrine cancer (LCNEC), large-cell carcinoma (LCC), squamous cell carcinoma (SqCC), and/or adenocarcinoma (AC) in the subject.

The invention provides various methods for classifying prostate cancers into subtypes. The classification methods may be used to diagnose or prognose prostate cancers. In one embodiment, the subtypes are PCS1, PCS2, or PCS3. In one embodiment, the PCS1 subtype is most likely to progress to metastatic disease or prostate cancer specific mortality when compared to the PCS2 subtype or PCS3 subtype. In one embodiment, the PCS1 subtype is resistant to enzalutamide.

Growing community of inventors

Los Angeles, CA, United States of America

Sungyong You